USA: New York-based private equity firm Avista Capital Partners has completed the acquisition of Terrats Medical, a prominent dental prosthetics, abutments, and implants provider based in Spain. The acquisition was made from Miura Partners, with the financial terms remaining undisclosed.
Terrats Medical, established in 1947, specializes in manufacturing and marketing a diverse range of dental prosthetics and related products. The company serves a wide clientele including dental offices, laboratories, distributors, and original dental implant equipment manufacturers. With a strong international presence, Terrats exports over 95% of its products and operates in more than 50 countries.
Strategic Initiatives and Growth
Miura Partners, which has been investing in Terrats since 2020, has supported the company in implementing strategic initiatives that have significantly boosted its sales.
According to Terrats CEO Roger Terrats, “Our vision for the next stage will be very consistent and focused on global growth, with a top-notch product suite and strong sales network that will be fortified in the coming years.” These initiatives include enhancing direct sales, launching an implantology business, advancing digital strategies, and acquiring distributors in the US and Sweden.
Avista’s acquisition of Terrats is anticipated to bolster the company’s growth, particularly in the US market. Roger Terrats further added, “Additionally, we look forward to continuing to invest in our production and our team.”
The move aims to enhance Terrats’ financial standing and global positioning, facilitating further expansion and exploration of new growth opportunities. Post-acquisition, the founders of Terrats Medical will continue to lead the business, demonstrating their commitment to its future success.
Reinvestment and Advisory Services
Both the founders of Terrats and Miura Partners have reinvested in the company, underscoring their confidence in its growth potential. Advisory services for the transaction were provided by reputable firms including Moelis & Company, KPMG, Clifford Chance, Deloitte, Ropes & Gray, and Uría, covering various aspects of the acquisition process.
The information and viewpoints presented in the above news piece or article do not necessarily reflect the official stance or policy of Dental Resource Asia or the DRA Journal. While we strive to ensure the accuracy of our content, Dental Resource Asia (DRA) or DRA Journal cannot guarantee the constant correctness, comprehensiveness, or timeliness of all the information contained within this website or journal.
Please be aware that all product details, product specifications, and data on this website or journal may be modified without prior notice in order to enhance reliability, functionality, design, or for other reasons.
The content contributed by our bloggers or authors represents their personal opinions and is not intended to defame or discredit any religion, ethnic group, club, organisation, company, individual, or any entity or individual.